Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.

Teresa Delgado-GoñiTeresa Casals GalobartSlawomir WantuchDeimante NormantaiteMartin O LeachSteven R WhittakerMounia Beloueche-Babari

Published in: British journal of cancer (2019)

Altogether, our data highlight heterogeneity in metabolic adaptations during acquired resistance to vemurafenib in BRAF-mutant melanoma, potentially uncovering key clinically-relevant mechanisms for combinatorial therapeutic targeting.

Keyphrases

wild type
oxidative stress
metastatic colorectal cancer
electronic health record
high intensity
cancer therapy
fatty acid